Following the significant inquiry, the top10 compounds including metyrapone, gefitinib, dilazep, aminopentamide, methoxsalen, forskolin, CGP-37157, IKK2-inhibitor, vidarabine and TG-101348 with the highest negative scores were considered to be potential pharmacological therapeutic agents for the treatment of CKD-related CAVD (Fig. 6A). This evidence concerns the gene IKBKB and congenital bilateral aplasia of vas deferens from CFTR mutation.